MK-6837
/ Merck (MSD)
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 29, 2025
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
(clinicaltrials.gov)
- P1 | N=168 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting
Enrollment closed • Monotherapy • Oncology • Solid Tumor
August 18, 2025
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
(clinicaltrials.gov)
- P1 | N=204 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | N=100 ➔ 204
Enrollment change • Monotherapy • Oncology • Solid Tumor
July 24, 2024
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
(clinicaltrials.gov)
- P1 | N=100 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting
Combination therapy • Enrollment open • Metastases • Monotherapy • Oncology • Solid Tumor
June 14, 2024
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
(clinicaltrials.gov)
- P1 | N=100 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC
Combination therapy • Metastases • Monotherapy • New P1 trial • Oncology • Solid Tumor
1 to 4
Of
4
Go to page
1